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ABSTRAK ABSTRACT
Tujuan: Menelaah diagnosis dan penanganan ke keringan pada
vagina pada perempuan menopaue
Metode: Kajian pustaka
Hasil: Kekurangan estrogen berdampak negatif terhadap vagina
dan saluran kemih. Vagina menjadi kering (atrofi) sehingga
merasa sakit ketika melakukan hubungan seks. Diagnosis atrofi
vagina berupa keluhan vagina kering (75%), nyeri sanggama
(38%), gatal dan keputihan. Tidak jarang pasien mengeluh nyeri
berkemih, sering kencing malam hari, inkontinensia dan infeksi
saluran kemih berulang. Mukosa servik, vagina dan vulva tipis.
Vagina mudah berdarah. Diagnosis dapat juga ditegakkan dengan
mengukur pH vagina dengan menggunakan kertas likmus dan
sitologi vagina. Penanganannya adalah dengan pemberian
estrogen lokal jenis estrogen lemah (E3) berupa krim. Pemberian
E3 krim tidak perlu dikombinasikan dengan progestogen. Jenis
TH lokal yang lain adalal DHEA krim. Pemberian estrogen kuat
(E2) atau equin estrogen harus selalu dikombinasikan dengan
progestogen untuk mencegah hiperplasia endometruim, baik
diberikan secara lokal maupun secara sistemik. E3 krim juga
aman diberikan pada perempuan dengan kanker payudara jang
mengalami atrofi vagina
Simpulan: Kekurangan estrogen menyebabkan atrofi vagina
dengan keluhan vagina kering.Atrofi vagina juga menyebabkan
gangguan berkemih . Diagnosis berdasarkan gejala, pemeriksaan
pH vagina dan sitologi vagina. Penanganan nya adalah dengan
pemberian TH dengan estrogen. E3 krim paling efektif meng-
hilangkan keluhan yang diakibatkan oleh vagina kering dan
keluhan yang diakibatkan oleh kandung kemih.
Kata kunci: vagina kering, diagnosis, penanganan, menopaue,
terapi hormon (TH)
Objective: To review the diagnosis and management of vaginal
dryness in menopausal women
Methods: Literature review
Results: Lack of estrogen negatively impacts the vagina and the
urinary tract. The vagina becomes dry (atrophic) and then causing
pain during sexual intercourse. Vaginal atrophy can be diagnosed
in the form of vaginal dryness (75%), painful sexual intercourse
(38%), itching and discharge complaints. Sometimes the patient
complained pain in urinating, frequent night urination, in-
continence and recurrent urinary tract infections. Mucose of the
cervix, vagina and vulva are thin. Vagina can bleed easi-
ly. Diagnosis can also be made by measuring the pH of the vagina
by using litmus paper and vaginal cytology. The management
involves administration of local estrogen treatment using weak
estrogen (E3) in the form of a cream. E3 cream does not need to
be combined with progestogen. Other type of local hormonal
therapy (TH) is DHEA cream. Giving a strong estrogen (E2) or
equin estrogen should always be combined with progestogen to
prevent endometrium hyperplasia, either administered locally or
systemically. E3 cream is also safe in women with breast cancer
who experienced vaginal atrophy.
Conclusion: Lack of estrogen causes vaginal atrophy with
symptoms of vaginal dryness. Vaginal atrophy also causes urinary
problems. Diagnosis is based on symptoms, examination of
vaginal pH and vaginal cytology. The management is by adminis-
tering HT with estrogen. E3 creams is the most effective in
relieving complaints caused by vaginal dryness and complaints
caused by the bladder.
Keywords: vaginal dryness, diagnosis, management, menopause,
hormonal therapy (HT)
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INTRODUCTION
Female genitalia and urinary tract’s embryology are
associated due to the same origin. The two organs need
estrogen. Vaginal dryness is inseparable with vaginal
atrophy. Other terms for vaginal atrophy are vulvo-
vaginalatrophy or urogenital atrophy. In reproductive
age the estrogen level is sufficient, the vaginal wall is
thick, elastic, the vaginal rugae are intact, blood flow to
vagina is increasing, vaginal lubrication is good and
acidic vaginal pH (pH <5). Vaginal atrophy is estimated
to occur in 10-40% of women, mostly caused by
estrogen deficiency. It is commonly found at menopau-
sal age and the elderly, but may also occur at a young
age due to premature menopause. Premature menopause
can occur due to the removal of the two ovaries,
hipotamic amenorrhea, hyperprolactinemia, lactation,
the use of antiestrogen drugs, anticancer drugs and
radiation1
DIAGNOSIS
Menopause and from symptoms caused by vaginal
atrophy such as vaginal dryness (75%), painful sexual
intercourse (38%), vaginal itching and discharge2.
Because internal genital and urinary tract are originated
from the same source in embryology, the patient also
complained of painful urination, frequent night urina-
tion, incontinence and recurrent urinary tract infection3.
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PHYSICAL EXAMINATION
In internal examination of vaginal wall the mucous of
the cervix, vagina and vulva epithelium are thin and the
lower portio bleed easily. There is no vaginal rugae, the
vaginal opening retracts, vagina looks pale and some-
times there are visible petechial or signs of inflam-
mation. Because of the acidic vaginal pH (3.5-5.0) fell
into alkaline pH (6.0 to 8.0), pathogens including fungi
and bacteria (coli) are easily found, causing vaginal
odor3. Spontaneous or postcoital micro/ macroulceration
can also be found. In speculum examination, the vagina
bleed easily and very painful for the patients. In women
who are not sexually active or rarely do sexual inter-
course, vaginal atrophy can lead to vaginal narrowing
and shortening4.
Objectively, there are two ways of examination for the
diagnosis and evaluation of treatment, it is by measuring
vaginal pH by using litmus paper and the vaginal
maturation index (% superficial cells are low compared
with intermediate cells and parabasal cells)
MANAGEMENT OF VAGINAL ATROPHY
The symptoms caused by vaginal atrophy should not be
underestimated, especially the impact on the sexual
quality5. 50-70% of women with vaginal atrophy symp-
toms do not seek doctor’s help to get treatment, because
they thought that the complaint is a natural process and
sexual intercourse is not necessary anymore6,7. Most of
women are shy to be caught by doctor if they had not
had sex for a long time. Instead of a doctor, the women
tried to deal with it in her own way, which is not having
sex anymore. What about the husband who did not
experience andropause, is the husband ready to abstain
from intercourse for years? Not the wife but the
husband who frequently visit the doctor to want to know
why his wife does not want to have sex again.
Vaginal atrophy and urinary symptoms are mostly
caused by estrogen deficiency, therefore the rational
treatment is estrogen administration. Estrogen prepara-
tions can be administered in systemic or local. The most
effective and safe treatment is a local vaginal estrogen
because it does not have a systemic impact. Local
estrogen can be administered in the form of tablets/
suppositories, creams, or vaginal rings. Local estrogen
might contain strong estrogen such as estradiol (E2) and
estrogen equin conjugate, and contain a weak estrogen
such as estriol (E3) and estrone (E4). The use of strong
estrogen can trigger the growth of endometrium leading
to endometrial hyperplasia and endometrial cancer in
the future8. Therefore any strong estrogen adminis-
tration should always be combined with proges-
togen. Endometrial hyperplasia or cancer were not
found in short-term use for 1-2 years with a low dose
(25 ug)9. In the instructions issued by the International
Menopause Society and The North American Meno-
pause Society, the use of low dose estrogen locally does
not need additional progestogen10,11.
Of all types of local estrogen, estriol cream is the most
widely used. It works very effectively to eliminate
complaints caused by vaginal atrophy or complaints
caused by urinary tract despite of its weak nature. Weak
estrogen has no systemic effect at all so it does not need
to be combined with progestogen. It does not cause a
venous thromboembolism and may even be given to
women with breast cancer12,13.
Not only estrogen receptors, but vulva and vagina also
have androgen receptors, therefore androgen might be
administered for women with vaginal atro-
phy. Combination of estrogen with testosterone cream
increase sexual desire of women, so that women have
the desire for sex, but unfortunately testosterone has
systemic effects. Free testosterone levels in the blood
reaches 54%14. Research is still continue to see the
effect of the vaginal ring containing E2 and testosterone
cream 1% in women with breast cancer who experience
vaginal atrophy. Giving DHEA (dehydroepiandro-
sterone) is very effective in relieving local complaints
caused by vaginal atrophy, and the results was already
visible within two weeks15. In order to get a good
resorption, the cream is placed near the cervix or
posterior fornix. The lowest resorption is when it is
placed in the distal vagina.
Giving oral tablet estrogen or estrogen + progestogen
also can eliminate the complaints of vaginal atro-
phy. However, oral administration is still debatable,
especially against the risk of breast cancer. Research by
Women's Health Initiative (WHI) reported that estrogen
combined with progestogen increased the incidence of
breast cancer, but estrogen alone in women without
uterus decreased breast cancer incidence16,17. Keep in
mind that the WHI study is heavily criticized, many
errors were found in its methodology. Oral adminis-
tration cannot eliminate complaints quickly compared to
the local administration.
In September and October 2014 results of a research
said that in postmenopausal women treated with HT for
10 years there was no breast cancer found18. There was
also no breast cancer found in transdermal adminis-
tration of low dose HT, either the combination or
not19,20. The incidence of breast cancer is not much
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different among women using HT with women who
gain weight 5 kg, or women who consume alcoholic
drinks two glasses per day21-23.
OLD MANAGEMENT
Repair of vaginal cytology and blood flow to the atro-
phic vaginal wall usually only can be seen after several
weeks of treatment. The maximum results obtained after
several months of treatment. Vaginal pain disappeared
after 6-12 months of treatment24. In the long-term use
(years) a lower dose is always used. Sometimes after the
treatment is stopped, the complaints arise. Women
discontinued treatment because existing drugs available
are only for 3-6 months, and women follow that advice.
The benefits of estrogen against urine incontinence are
still debatable among experts. Until now, the benefits of
estrogen can only be seen in women with stress
incontinence. Improvement of urethral pressure profile
in women with stress incontinence is already visible
after four - six weeks of estrogen administration, how-
ever, to get the better results the long term use is
recommended2. Estrogen administration also decrease
the incidence of urogenital infections and episodes
incontinence in elder women. It improves the vaginal
flora and relieves vaginal mucosal atrophy25.
LOCAL ESTROGEN’S SIDE EFFECT
Side effects on the administration of estriol cream is
almost never found. However creams containing estra-
diol or conjugate equin estrogen sometimes cause
irritation of the vagina, vaginal discharge, bleeding,
pelvic pain, breast tenderness and neuropathy. Studies
have proven that there is no thromboembolic event or
increase the incidence of metastasis in women with
breast cancer treated with local estrogen. Note that
when a severe vaginal atrophy are not treated, then there
will be complications such as recurrent cystitis until
pyelonephritis. 30-100% of women with breast cancer
or gynecologic cancer experienced sexual dysfunction26.
In women with cervical cancer, ovarian cancer or
endometrium cancer who are undergoing chemotherapy
or radiation and complain vaginal atrophy, may HT be
given? For breast cancer all experts agree that local
estrogen should be the treatment, but for gynecologic
cancer there is still no agreement. The efficacy and
safety of Complementary Alternative Medicine (CAM)
for women with complaints caused by vaginal atrophy
are still cannot be proven27.
Archeologist is the best husband a woman can have,
the older she gets, the more he is interested in her
Agatha Christie (1890-1976)
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